Researchers at NSHA and Dalhousie University are global leaders in defining the concept of frailty. They’ve developed tools for quantifying frailty that are now used in Canada, the United Kingdom, the United States, China and other parts of the world.
Researchers at NSHA are pioneering ways to improve atrial fibrillation (AF) patients’ health and quality of life, partnering with Halifax-based Kinduct Technologies to develop and pilot a virtual clinic to follow patients with AF.
Thanks to the Nova Scotia Antidote Program—launched as a pilot project in the Central Zone in 2005 and rolled out province-wide in 2009—people who ingest toxic doses of medications and other potentially dangerous substances can access an antidote no matter where in the province they live.
Through research, teaching and clinical application, Dr. Robar, who serves as the Chief of Medical Physics at Nova Scotia Health Authority, has helped develop innovative techniques that have contributed to better patient care not only in Nova Scotia, but across the world.